Litcius/Paper detail

Chemotherapy With Or Without Pembrolizumab Followed By Maintenance With Olaparib Or Placebo For First-Line Treatment Of Advanced BRCA Non-Mutated Epithelial Ovarian Cancer: Results From The Randomized Phase 3 ENGOT-OV43/GOG-3036/KEYLYNK-001 Study

Ignace Vergote, David Cibula, Matthew A. Powell, Els Van Nieuwenhuysen, Samet Topuz, Antonio González‐Martín, Keiichi Fujiwara, Sufia Safina, Andrea Bagaméri, Matthew J. Oliver, Jung-Yun Lee, Giovanni Scambia, Jacob Korach, Chien‐Hsing Lu, Nicoletta Colombo, Radosław Mądry, Wei Jing, Sarper Toker, Karin Yamada, John R. Moroney

2025International Journal of Gynecological Cancer17 citationsDOIOpen Access PDF

Topics & Concepts

MedicineOlaparibPembrolizumabOncologyOvarian cancerChemotherapyPlaceboInternal medicineEpithelial ovarian cancerCancerImmunotherapyPathologyPoly ADP ribose polymerasePolymeraseGeneBiochemistryChemistryAlternative medicinePARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentBRCA gene mutations in cancer
Chemotherapy With Or Without Pembrolizumab Followed By Maintenance With Olaparib Or Placebo For First-Line Treatment Of Advanced BRCA Non-Mutated Epithelial Ovarian Cancer: Results From The Randomized Phase 3 ENGOT-OV43/GOG-3036/KEYLYNK-001 Study | Litcius